About AltheaDx
AltheaDx is a company based in San Diego (United States) founded in 2009 was acquired by Castle Biosciences in April 2022. AltheaDx has raised $94.73 million across 14 funding rounds from investors including Castle Biosciences, WuXi AppTec and 6 Dimensions Capital. AltheaDx offers products and services including IDgenetix, DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and DecisionDx-UM. AltheaDx operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Altheadx, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$94.73 M (USD)
in 14 rounds
-
Latest Funding Round
$3.73 M (USD), Series D
Dec 04, 2020
-
Investors
Castle Biosciences
& 5 more
-
Employee Count
Not available
-
Acquired by
Castle Biosciences
(Apr 04, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AltheaDx
AltheaDx offers a comprehensive portfolio of products and services, including IDgenetix, DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and DecisionDx-UM.
Analyzes genes to personalize mental health medications and predict responses.
Evaluates melanoma risk and guides treatment decisions based on genetic profiling.
Assists in assessing squamous cell carcinoma prognosis and management options.
Predicts cancer risk in gastroenterology through gene expression analysis.
Supports uveal melanoma diagnosis and metastatic risk evaluation.
People of AltheaDx
Unlock access to complete
Unlock access to complete
Funding Insights of AltheaDx
AltheaDx has successfully raised a total of $94.73M across 14 strategic funding rounds. The most recent funding activity was a Series D round of $3.73 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AltheaDx
AltheaDx has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Castle Biosciences, WuXi AppTec and 6 Dimensions Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life-Sciences focused early and growth stage VC firm funding companies in China & the US
|
Locked | Locked | Locked | |
|
Private equity and hedge fund investments in healthcare are managed.
|
Locked | Locked | Locked | |
|
Investment in conscious healthcare businesses is facilitated by ALMA.
|
Locked | Locked | Locked |
Investor details for AltheaDx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AltheaDx
Investment portfolio details for AltheaDx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AltheaDx
Detailed financials for AltheaDx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Altheadx Comparisons
Peer comparison for AltheaDx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AltheaDx
AltheaDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| Locked | Locked | Locked |
Diagnostic services are provided through laboratories and radiology units.
|
Detailed competitors of AltheaDx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Altheadx
Complete news archive for AltheaDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AltheaDx
AltheaDx was founded in 2009.
AltheaDx is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
AltheaDx is a funded company, having raised a total of $94.73M across 14 funding rounds to date.
AltheaDx, Inc. provides molecular diagnostics and PCR-based services. It offers molecular biomarker discovery, assay development, assay validation, and prospectiveretrospective clinical trial testing services. The company also provides gene expression and genotyping analysis for pre-clinical and clinical applications. In addition, it offers discovery services, such as microarray analysis, real-time PCR, next-gen sequencing, quantitative PCR, mutation scanning, data analysis, race assay, and therapeutic siRNA; and diagnostic development services. Further, the company provides clinical trial services, such as enhanced clinical trial, predictive drug response, patient stratification and monitoring.
AltheaDx's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
AltheaDx offers IDgenetix, DecisionDx-Melanoma, DecisionDx-SCC, TissueCypher, and DecisionDx-UM.
AltheaDx has 6 investors. Key investors include Castle Biosciences, WuXi AppTec, 6 Dimensions Capital, Ally Bridge Group, and ALMA Life Sciences.